Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Expected to Announce Quarterly Sales of $29.79 Million

Wall Street analysts expect Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) to report $29.79 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s earnings. The lowest sales estimate is $25.84 million and the highest is $33.73 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share reported sales of $43.09 million during the same quarter last year, which indicates a negative year-over-year growth rate of 30.9%. The firm is expected to issue its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will report full year sales of $29.79 million for the current year, with estimates ranging from $165.43 million to $173.32 million. For the next financial year, analysts anticipate that the company will report sales of $111.38 million per share, with estimates ranging from $105.03 million to $117.72 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share.

AVDL has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. BidaskClub raised shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Roth Capital set a $14.00 price target on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the company a “buy” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has an average rating of “Hold” and an average price target of $21.50.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) opened at $8.99 on Wednesday. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.01. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a fifty-two week low of $7.52 and a fifty-two week high of $12.30. The company has a market cap of $369.98, a price-to-earnings ratio of 4.66 and a beta of 1.31.

In other news, Director Craig R. Stapleton purchased 140,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $8.67 per share, with a total value of $1,213,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Craig R. Stapleton sold 254,265 shares of the business’s stock in a transaction on Monday, November 27th. The shares were sold at an average price of $9.35, for a total transaction of $2,377,377.75. Following the completion of the transaction, the director now directly owns 253,413 shares of the company’s stock, valued at approximately $2,369,411.55. The disclosure for this sale can be found here. 5.07% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in AVDL. JPMorgan Chase & Co. acquired a new position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 2nd quarter valued at $733,000. PNC Financial Services Group Inc. grew its holdings in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after buying an additional 10,532 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 2nd quarter valued at $259,000. Stifel Financial Corp grew its holdings in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 4.3% in the 2nd quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock valued at $667,000 after buying an additional 2,500 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 2nd quarter worth $24,100,000. 64.92% of the stock is owned by institutional investors.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-expected-to-announce-quarterly-sales-of-29-79-million.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply